Industry News

Abyrx receives FDA clearance for absorbable hemostatic bone putty

The FDA has cleared Abyrx’s new Absorbable Hemostatic Bone Putty for clinical use in the United Stated, expanding the company’s surgical hemostat product offerings.

The ready-to-use Absorbable Hemostatic Bone Putty (AHBP) does not require mixing or stirring and achieves hemostasis by mechanical tamponade. According to a company press release, the putty consists of water-soluble and dissolvable components that completely absorb within days after surgery. Abryx offers AHBP in several sizes.

“AHBP and other products under development complement our Hemasorb products and will provide surgeons with more options to treat their patients and help enable hospitals to reduce costs,” John J. Pacifico, president and chief executive officer of Abryx, stated in the release.

The FDA has cleared Abyrx’s new Absorbable Hemostatic Bone Putty for clinical use in the United Stated, expanding the company’s surgical hemostat product offerings.

The ready-to-use Absorbable Hemostatic Bone Putty (AHBP) does not require mixing or stirring and achieves hemostasis by mechanical tamponade. According to a company press release, the putty consists of water-soluble and dissolvable components that completely absorb within days after surgery. Abryx offers AHBP in several sizes.

“AHBP and other products under development complement our Hemasorb products and will provide surgeons with more options to treat their patients and help enable hospitals to reduce costs,” John J. Pacifico, president and chief executive officer of Abryx, stated in the release.